James Karrels - MacroGenics CFO, Sr. VP and Corporate Secretary
| MGNX Stock | USD 3.41 0.07 2.10% |
CFO
Mr. James Karrels is Chief Financial Officer, Senior Vice President, Secretary of the Company. Mr. Karrels has joined us in May 2008 and has approximately 25 years of experience in finance, with a significant portion of those working for, or on behalf of, life sciences companies. Prior to joining us, he served as Executive Director of Finance at Jazz Pharmaceuticals, Inc., where he was responsible for the companys financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels spent 11 years in the Investment Banking Group at Merrill Lynch, serving as a Director in the Global Healthcare Group since 2008.
| Age | 57 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Address | 9704 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 301 251 5172 |
| Web | https://www.macrogenics.com |
MacroGenics Management Efficiency
The company has return on total asset (ROA) of (0.2215) % which means that it has lost $0.2215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6217) %, meaning that it created substantial loss on money invested by shareholders. MacroGenics' management efficiency ratios could be used to measure how well MacroGenics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.03 in 2024. Return On Capital Employed is likely to rise to -0.66 in 2024. At this time, MacroGenics' Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 245.6 M in 2024, whereas Total Assets are likely to drop slightly above 287.5 M in 2024.Similar Executives
| Found 4 records | CFO Age | ||
| Marc Belsky | Kezar Life Sciences | 69 | |
| Lucy CPA | AN2 Therapeutics | 65 | |
| Adam Levy | Mineralys Therapeutics, Common | 46 | |
| David JD | Pharvaris BV | 70 | |
Management Performance
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.22 |
MacroGenics Leadership Team
Elected by the shareholders, the MacroGenics' board of directors comprises two types of representatives: MacroGenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MacroGenics. The board's role is to monitor MacroGenics' management team and ensure that shareholders' interests are well served. MacroGenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MacroGenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ezio Bonvini, Senior Vice President- Research | ||
| Jeffrey JD, General VP | ||
| Scott MD, CEO President | ||
| Thomas Spitznagel, Senior Vice President - Bio Pharmaceutical Development and Manufacturing | ||
| Christopher MD, VP Communications | ||
| James Karrels, CFO, Sr. VP and Corporate Secretary | ||
| Lynn Cilinski, Principal Accounting Officer, VP, Controller and Treasurer | ||
| Jeffrey Peters, Vice President General Counsel | ||
| Ezio MD, Senior Officer | ||
| Eric Risser, Sr. VP of Bus. Devel. and Portfolio Management |
MacroGenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MacroGenics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.69) % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 52.15 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Shares Owned By Insiders | 2.64 % | ||||
| Shares Owned By Institutions | 93.67 % | ||||
| Number Of Shares Shorted | 5.1 M | ||||
| Price To Earning | (4.54) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.